# US 2019/0375857 A1 · Covalent heterobivalent antibody inhibitors and ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375857 A1
- Document ID: US20190375857A1
- Status: Published application
- Kind: A1
- Application number: 16/062,832
- Filed: 2016-12-19
- Published: 2019-12-12
- Earliest claimed: 2015-12-18
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame du Lac
- Inventors: Zihni Basar BILGICER; Peter Edward DEAK; Tanyel KIZILTEPE BILGICER; Michael William HANDLOGTEN; Jonathan Darryl ASHLEY
- Web page: https://patentgrep.com/patent/US20190375857A1

## CPC

- A61K 9/4866: {Organic macromolecular compounds}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 38/05: Dipeptides
- A61K 38/07: Tetrapeptides
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.

## Claims

### Claim 1

An antibody inhibitor of Formula I:
wherein
TM is a targeting moiety for an antigen binding site (ABS) wherein the targeting moiety comprises a) a mimotope of an allergen protein epitope peptide sequence, b) a peptidomimetic, or c) a small molecule hapten, each which have a selective electrostatic affinity for the ABS of an immunoglobulin;
TL is a targeting ligand for a conserved nucleotide binding site (NBS) of the immunoglobulin wherein the targeting ligand has a selective electrostatic affinity for the NBS located proximal to the ABS and between the heavy chain and light chain of the immunoglobulin;
FG is a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of an amino acid proximal to the NBS of an allergen reactive immunoglobulin; and
S1 is a variable length spacer comprising oligomers of ethylene glycol, amino acids, saccharides, hydrocarbons, fluorinated hydrocarbons, or combination thereof, wherein the spacer is conjugated by one or more lysine moieties and one or more amide bonds to TM, TL, and FG;
wherein when the antibody inhibitor bivalently binds to both the ABS and the NBS, the effective concentration of the reactive functional group (FG) near the amino acid of the immunoglobulin increases to irreversibly inhibit the immunoglobulin by the site-directed covalent bond formed by the inhibitor.

### Claim 2 (depends on 1)

The inhibitor of claim 1 wherein TL comprises a conjugate of a ligand which electrostatically binds to NBS with a Kd of less than 5 μM.

### Claim 3 (depends on 1)

The inhibitor of claim 1 wherein FG comprises a conjugate of an isothiocyanate, an isocyanate, an alkyne, a bromine, an acrylamide, or a maleimide.

### Claim 4 (depends on 1)

The inhibitor of claim 1 wherein S1 comprises a conjugate of the formula —(CH2—X—CH2CH2—X—CH2)y—, wherein X is O or NR wherein R is H or (C1-C4) alkyl, and y is 1 to 12.

### Claim 5 (depends on 1)

The inhibitor of claim 1 wherein TM comprises a conjugate of a) a mimotope of an allergen protein, wherein the allergen protein is from the primary sequence of Ara h 1, Ara h 2, Ara h 3, or Ara h 6, b) the peptide sequence of a peptidomimetic, wherein the peptidomimetic electrostatically binds to Rituximab, Trastuzumab or a pharmaceutical antibody, or c) a small molecule hapten, wherein the molecule is dinitrophenol, dansyl, penicilloyl, oxaliplatin or a drug having a molecular weight under 800 Daltons.

### Claim 6 (depends on 2)

The inhibitor of claim 2 wherein TL comprises a conjugate of 2-napthaleneacetic acid, indole-3-butyric acid, or fluorene.

### Claim 7

An antibody inhibitor of Formula II:
wherein
TM is a targeting moiety for an antigen binding site (ABS) wherein the targeting moiety comprises a) a mimotope of an allergen protein epitope peptide sequence, b) a peptidomimetic, or c) a small molecule hapten, each which have a selective electrostatic affinity for the ABS of an immunoglobulin;
TL is a targeting ligand for a conserved nucleotide binding site (NBS) of the immunoglobulin wherein the targeting ligand has a selective electrostatic affinity for the NBS located proximal to the ABS and between the heavy chain and light chain of the immunoglobulin;
FG is a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of an amino acid proximal to the NBS of an allergen reactive immunoglobulin;
S1 is a variable length spacer comprising one or more variable length ethylene glycol (EG1) spacers and one or more lysine (K1) spacers wherein each EG1 spacer and each spacer is linked by one or more amide bonds;
S2 comprises a variable length ethylene glycol (EG2) spacer and a lysine (K2) spacer linked by an amide bond; and
TG is a tag comprising a chromophore or a fluorophore;
wherein the ABS targeting moiety (TM), the NBS targeting ligand (TL), and the reactive functional group (FG) are conjugated to S and TM is further conjugated to a tag (TG) by a second spacer S2, wherein when the antibody inhibitor bivalently binds to both the ABS and the NBS, the effective concentration of the reactive functional group (FG) near the amino acid of the immunoglobulin increases to irreversibly inhibit the immunoglobulin by the site-directed covalent bond formed by the inhibitor, and the irreversibly inhibited immunoglobulin is tagged by the chromophore or the fluorophore.

### Claim 8 (depends on 7)

The inhibitor of claim 7 wherein the tag (TG) is fluorescein, dansyl, dinitrophenol, a rhodamine, a coumarin, a xanthene, a cyanine, or an Alexa Fluor.

### Claim 9 (depends on 7)

The inhibitor of claim 7 wherein,
TL is a conjugate of 2-napthaleneacetic acid, indole-3-butyric acid, or fluorene;
FG is a conjugate of isothiocyanate;
EG1 and EG2 are conjugates of the formula —(CH2—X—CH2CH2—X—CH2)y—;
X is O or NR wherein R is H or (C1-C4) alkyl;
y is 1 to 12; and
TM is a conjugate of a) a mimotope of an allergen protein, wherein the allergen protein is from the primary sequence of Ara h 1, Ara h 2, Ara h 3, or Ara h 6, b) the peptide sequence of a peptidomimetic, wherein the peptidomimetic binds to Rituximab, Trastuzumab or a pharmaceutical antibody, or c) a small molecule hapten, wherein the molecule is dinitrophenol, dansyl, penicilloyl, oxaliplatin or a drug having a molecular weight under 800 Daltons.

### Claim 10 (depends on 7)

The inhibitor of claim 7 wherein FG is reactive to the amino moiety of lysine proximal to the NBS of an allergen reactive immunoglobulin.

### Claim 11

An antibody inhibitor of Formula III:
wherein
TM is a targeting moiety for an antigen binding site (ABS) wherein the targeting moiety comprises a) a mimotope of an allergen protein epitope peptide sequence, b) a peptidomimetic, or c) a small molecule hapten, each which have a selective electrostatic affinity for the ABS of an immunoglobulin;
TL is an optional targeting ligand for a conserved nucleotide binding site (NBS) of the immunoglobulin wherein the targeting ligand has a selective electrostatic affinity for the NBS located proximal to the ABS and between the heavy chain and light chain of the immunoglobulin;
FG is an optional reactive functional group capable of forming a site-directed covalent bond to the amine moiety of an amino acid proximal to the NBS of an allergen reactive immunoglobulin;
wherein the inhibitor comprises at least one of TL or FG;
EG1 is a variable length spacer comprising one or more spacers of the formula —(CH2—X—CH2CH2—X—CH2)y— wherein the —(CH2—X—CH2CH2—X—CH2)y— spacer is linked to one or more K1 spacers;
y is 1 to 12;
X is O or NR wherein R is H or (C1-C4) alkyl;
K1 is a spacer comprising one or more lysine moieties;
EG2 is an optional variable length spacer comprising the formula —(CH2—X—CH2CH2—X—CH2)y—;
K2 is an optional spacer comprising a lysine moiety;
wherein the spacers EG1, EG2, K1, K2, and —(CH2—X—CH2CH2—X—CH2)y— are linked by one or more amide bonds; and
TG is an optional tag comprising a chromophore or a fluorophore;
wherein the ABS targeting moiety (TM), the NBS targeting ligand (TL), and the reactive functional group (FG) are conjugated to K1, EG1 and EG2, and TM is further conjugated to an optional tag (TG) by K2 and EG2, wherein when the antibody inhibitor bivalently binds to both the ABS and the NBS, the effective concentration of the reactive functional group (FG) near the amino acid of the immunoglobulin increases to irreversibly inhibit the immunoglobulin by the site-directed covalent bond formed by the inhibitor, and the irreversibly inhibited immunoglobulin is tagged by the chromophore or the fluorophore when the inhibitor contains TG.

### Claim 12 (depends on 11)

The inhibitor of claim 11 wherein bivalent binding of TM and TL to the immunoglobulin synergistically enhance the avidity of the inhibitor.

### Claim 13 (depends on 11)

The inhibitor of claim 11 wherein FG is reactive to the amino moiety of lysine proximal to the NBS of an allergen reactive immunoglobulin.

### Claim 14 (depends on 11)

The inhibitor of claim 11 wherein TL comprises a conjugate of 2-napthaleneacetic acid, indole-3-butyric acid, or fluorene.

### Claim 15 (depends on 11)

The inhibitor of claim 11 wherein FG comprises a conjugate of isothiocyanate.

### Claim 16 (depends on 11)

The inhibitor of claim 11 wherein the inhibitor is:
wherein Peptide is a targeting peptide to Trastuzumab;
wherein Peptide is a targeting peptide to Trastuzumab;
wherein Peptide is targeting peptide to Trastuzumab;
wherein Peptide targeting peptide to Trastuzumab;
wherein Peptide targeting peptide to Rituximab;

### Claim 17 (depends on 1)

A method of inhibiting or reducing the severity of an allergic reaction comprising administering an effective amount of the inhibitor of claim 1 to a subject a) prior to exposure of the subject to an allergen, b) after exposure of the subject to an allergen, c) during an allergic response of the subject to an allergen, or d) prior to immunotherapy desensitization of a subject requiring immunotherapy desensitization, wherein inhibition of the immunoglobulin antibody to the allergen prevents degranulation of mast cells and basophils thereby substantially lowering the allergic response of the subject to the allergen.

### Claim 18 (depends on 17)

The method of claim 17 wherein the inhibitor is co-administered with epinephrine to mitigate an anaphylaxis response in a subject exposed to an allergen.

### Claim 19 (depends on 1)

A method of measuring the reaction kinetics of degranulation in an assay comprising adding a measured aliquot or a series of measured aliquots of the inhibitor of claim 1 to a) a monoclonal antibody in-vitro assay, or b) a blood serum in-vitro assay, to determine the rate of degranulation.

### Claim 20 (depends on 1)

A method of modulating immunological expression of T-cell receptors, B-cell receptors, or a combination thereof, by a) administering an effective amount of the inhibitor of claim 1 to a subject, or b) adding a measured amount of the inhibitor of claim 1 to an immunological in-vitro assay, to determine a dose-response relationship of the inhibitor and an immune response.

### Claim 21 (depends on 6)

A method for analyzing antibodies comprising tagging an antibody in an in-vitro assay with the inhibitor of claim 6 and analyzing the assay by flow-cytometry or ELISA to quantitate inhibition and provide feedback to a) the design of an inhibitor, b) the structure and function of an immunoglobulin, or c) the concentration of an immunoglobulin in a sample.
